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Abstract
 
Background
 
A 31-year-old woman presented with a 5-year history of painful ulcerations, 
palpable purpura, porcelain-white atrophic scars of the malleolar region and dorsal aspect of the 
feet, livedo reticularis on the limbs, arthralgia, xerophthalmia, and xerostomia.
 
Methods
 
Skin biopsy revealed vessel wall hyalinization and thrombosis of the 
microvasculature with a very scarce dermal inflammatory infiltrate. Biopsy of the oral mucosa 
showed mononuclear infiltration of an intralobular duct of a salivary gland.
 
Results
 
Laboratory studies, including autoantibodies and inflammation markers, were normal, 
except for a positive rheumatoid factor. Coagulation screening revealed C677T 
methylenetetrahydrofolate reductase (MTHFR) mutation, with a normal serum homocysteine. 
The patient was treated with oral methylprednisolone (32 mg/day with progressive reduction) 
and enoxaparin (20 mg/day subcutaneously), with complete ulcer healing within 4 months.
 
Conclusion
 
Livedoid vasculitis or vasculopathy has not been referred to previously in 
association with Sjögren’s syndrome, but may be associated with other autoimmune disorders 
and anomalies of coagulation, namely factor V Leiden mutation, protein C deficiency, and 
MTHFR mutation, associated or not with hyperhomocysteinemia, a condition that seems to 
confer an increased risk of recurrent arterial and venous thrombosis. We stress the importance 
of anticoagulant therapy for ulcer healing and for the prevention of other thrombotic events.
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Introduction
 
Livedoid vasculitis (LV), also known as livedoid vasculopathy
or livedo with summer/winter ulcerations, was first described
by Bard and Winkelmann
 
1
 
 in 1967 as a chronic vaso-occlusive
disorder of small dermal vessels affecting mainly young and
middle-aged women. It is characterized by livedo reticularis
with recurrent and painful ulcerations of the lower limbs, with
winter or summer exacerbations, that progress to porcelain-
white, stellate, atrophic scars surrounded by hyperpigmenta-
tion and telangiectasia, often referred to as “atrophie blanche
of Millian”. Histopathology reveals the typical pattern of
segmental hyalinization, endothelial swelling, and throm-
botic occlusion of dermal arterioles, surrounded by a scarce
perivascular lymphocytic infiltrate, without leukocytoclasia.
 
1
 
LV may be associated with autoimmune diseases, such as
antiphospholipid syndrome, lupus erythematosus, or sclero-
derma,
 
1–7
 
 which may have associated coagulation disorders,
or with thrombogenic disorders, such as factor V Leiden
mutation,
 
5–8
 
 protein C deficiency,
 
9,10
 
 Sneddon’s syndrome,
 
11
 
and methylenetetrahydrofolate reductase (MTHFR) mutation,
associated or not with hyperhomocysteinemia.
 
5,12
 
We describe a patient with primary Sjögren’s syndrome
(SS) and LV with persistent ulcers on the lower limbs associ-
ated with a hypercoagulability state: homozygosity for the
C677T MTHFR mutation.
 
Case Report
 
A 31-year-old woman was referred to the Department of
Dermatology with a 5-year history of persistent, deep, very
painful, bilateral, symmetric ulcers of the lower limbs resistant
to multiple therapies [hyperbaric oxygen, antiplatelet drugs,
pentoxifylline, intravenous immunoglobulin (IVIG)]. During
the last year, the patient had also complained of Raynaud’s
phenomenon, progressive xerostomia, and xerophthalmia.
For the last 3 months, she reported both inflammatory arthral-
gia, affecting mainly the feet and ankles with morning stiffness
lasting around 30 min, and mechanical arthralgia affecting the
hands. She had undergone an uncomplicated pregnancy 5 years
previously and had used oral contraceptives for 2 years. Her
personal and family medical histories were irrelevant.
On the lower limbs, mainly on the malleolar region and
dorsal aspect of the feet, there were several deep ulcers,
 International Journal of Dermatology
 
 2007, 
 
46
 
, 431–434 © 2007 
 
The International Society of Dermatology
 
432 Pharmacology and therapeutics
 
Livedoid vasculopathy and hypercoagulability in Sjögren’s syndrome
 
Cardoso
 
 et al.
 
between 0.5 and 2 cm in diameter, with a purpuric and
necrotic border, surrounded by porcelain-white scars,
telangiectasia, hyperpigmentation, and palpable purpura
(Fig. 1). Livedo reticularis with an irregular pattern was
present on the lower and upper limbs. Arterial pulses in the
lower extremities were full and symmetric, and there was no
edema. There was no clinical evidence of arthritis.
A skin biopsy from a palpable purpuric lesion showed
endothelial swelling and focal hyalinization of the walls of
small dermal vessels with intraluminal thrombosis of the
whole lumina without an inflammatory infiltrate or leuco-
cytoclasia, aspects compatible with segmental hyalinizing
vasculitis (Figs 2 and 3). No immunoglobulin or complement
deposition was found on direct immunofluorescence.
A biopsy of the oral mucosa revealed, in a single lobule of
a salivary gland, a dense mononuclear infiltrate around an
intralobular duct. Schirmer’s test values were 0 mm for the
left eye and 2 mm for the right eye, results suggestive of SS.
Non-invasive venous Doppler, chest X-ray, and abdominal
scan were normal.
Routine and other complementary laboratory blood tests,
including platelet count, prothrombin time, activated partial
thromboplastin time, fibrinogen and fibrin degradation
products, electrophoretic proteinogram, immunoglobulin
fractions, C3 and C4, circulating immune complexes, cryo-
globulins, antinuclear (ANA) and antineutrophilic cytoplasmic
(ANCA) antibodies, lupus anticoagulant, anticardiolipin
antibodies, venereal disease research laboratory (VDRL) test,
C-reactive protein, erythrocyte sedimentation rate, and hepa-
titis B and C serologies were negative or within the normal
range, except for a repeatedly positive rheumatoid factor
(50 IU/mL). With a clinical and histologic diagnosis of LV, we
further evaluated the following prothrombotic factors:
antithrombin III, proteins C and S, factors V, VIII, IX, factor
V G1691A (factor V Leiden), prothrombin G20210A, and
MTHFR. The patient was homozygous for the C677T muta-
tion in the MTHFR gene. Homocysteinemia measured
4 months later, and after stopping folic acid supplements for
3 weeks, was within normal limits.
Treatment was initiated with oral methylprednisolone
32 mg/day and, once the coagulation studies were concluded,
3 weeks later, subcutaneous enoxaparin 20 mg/day and oral
folic acid 5 mg/day. As pain subsided rapidly and ulcer healing
progressed, steroid was progressively tapered. At 4 months,
with complete resolution of the ulcers (Fig. 4), steroid was
stopped and enoxaparin was replaced by warfarin. Six
months thereafter, in the summer of 2005, although the
Figure 1 Painful, deep, symmetric ulcers of the malleolar region
Figure 2 Histopathologic examination of a skin biopsy 
revealing hyalinization of the small vessel walls of the upper and 
medial dermis without significant dermal inflammation 
(hematoxylin and eosin, ×40)
Figure 3 Intraluminal thrombosis of the small dermal vessels 
without inflammatory infiltrate or leukocytoclasia (periodic 
acid–Schiff stain, ×400)
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patient was on folic acid supplementation (5 mg/day) and
oral warfarin [international normalized ratio (INR) = 2–2.5],
she presented with painful, incipient, palpable purpura,
which, within 2 months, progressed to small ulcers in the
medial malleolar region of the left leg that responded slowly
to the reintroduction of enoxaparin. In which concerns SS the
patient maintains symptomatic treatment.
 
Discussion
 
Our patient had clinical and laboratory criteria consistent with
a diagnosis of SS (xerophthalmia, xerostomia, mononuclear
periductal infiltration of a salivary gland, and a positive rheu-
matoid factor), a primary form of SS with repeatedly negative
anti-Ro antibodies. For 5 years she had also suffered from
LV associated with a possible hypercoagulable state that
responded well to the low-molecular-weight heparin (LMWH),
enoxaparin, and was maintained under partial control on
coumarin derivatives.
Considered mostly as an idiopathic disease and described
initially as “livedoid vasculitis,” this entity is now mostly
referred to as “livedoid vasculopathy” because of the absence
of an inflammatory infiltrate, fibrinoid necrosis, or leuko-
cytoclasia in the process of dermal vessel occlusion, and the
reduced expression of serologic markers of inflammation
compared with other cutaneous vasculitides.
 
2
 
 In addition, LV
has been increasingly associated with disorders of coagulation
with thrombophilia, such as platelet aggregation defects,
 
13
 
protein C deficiency,
 
9,10
 
 factor V Leiden,
 
5–8
 
 antithrombin III
deficiency,
 
14,15
 
 Sneddon’s syndrome,
 
11
 
 and hyperhomo-
cysteinemia
 
12
 
 associated with the C677T MTHFR mutation.
 
5
 
The association of LV with systemic diseases, such as scleroderma,
lupus erythematosus, cryoglobulinemia, and antiphospholipid
syndrome,
 
2–5
 
 may be the result of an underlying endothelial
aggression or coagulation disorder that frequently is associ-
ated with these diseases. No reference has been found in the
literature concerning the association of LV and SS, and,
although it is an autoimmune disease, the association of SS
with antiphospholipid antibodies or coagulation defects has
not been reported. Cutaneous vasculitis with palpable purpura
occurs frequently in SS, especially in Ro-positive SS (not the
case in our patient), and is a result of small vessel leukocyto-
clastic vasculitis or hypocomplementemic urticarial vasculitis
with lymphocytic perivascular inflammation,
 
16
 
 not LV.
Therefore, this case may just be a coincidental association.
Although many cases of LV are still considered to be idio-
pathic, this may be the result of an incomplete study of the
coagulation parameters or of the necessity of the association
of minor disorders of coagulation in the same patient. In our
case, we found a homozygous state for mutation of the enzyme
MTHFR. This enzyme shunts methyl groups from DNA
synthesis to the methylation pathways, therefore converting
homocysteine to methionine. In C677T MTHFR mutation, a
C moiety is substituted for a T moiety at nucleotide 677 in the
encoding region of the MTHFR gene, converting the codon
for alanine to valine. Therefore, the final protein has decreased
enzyme activity and, consequently, patients develop a mild or
moderate hyperhomocysteinemia.
 
17–19
 
 Nevertheless, several
factors, including folic acid intake, may influence plasma
homocysteine levels,
 
18
 
 as may have occurred in our patient,
who was homozygous for the C677T MTHFR mutation but
had a normal value for homocysteine 3 weeks after stopping
folic acid supplements. Both hyperhomocysteinemia and the
C677T MTHFR mutation have been associated with an
increased risk of venous and arterial thrombosis in different
organs,
 
18,19
 
 although in some studies this is not so evident,
 
17
 
and some authors have suggested that other concomitant minor
thrombophilic disorders or a low folate status may be neces-
sary to increase the risk of arterial or venous thrombosis.
 
17,20
 
The mechanism of the effect of homocysteine on coagulation
is not completely understood, but 
 
in vitro
 
 studies have shown
that it interferes with the fibrinolytic and anticoagulant system
and may damage endothelial cells.
 
18
 
The therapy of LV is usually difficult and disappointing,
as shown by the wide list of treatments reported with very
irregular results: dapsone, corticosteroids, acetylsalicylic acid
and other platelet aggregation inhibitors, nicotinic acid,
pentoxifylline,
 
21
 
 the S2 serotoninergic blocker ketanserin,
 
22
 
hyperbaric oxygen,
 
23
 
 danazol and other fibrinolytic agents,
 
24
 
prostacyclin analogs such as iloprost,
 
25
 
 IVIG,
 
26
 
 and psoralen
plus UV-A (PUVA).
 
27
 
 Our case, previously submitted to
several of these treatments without benefit, represents
another example of the difficulty of LV therapy. In this case,
as in previously reported cases, a good response to LMWH
makes this a potential therapeutic possibility in the treatment
of LV,
 
24,28
 
 even in the absence of detectable coagulation
defects.
 
16,29
 
 Vitamin K antagonists may be used to replace
Figure 4 Complete healing of the ulcers after 4 months of 
subcutaneous enoxaparin 20 mg/day
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LMWH in some cases,
 
15
 
 as occurred in our patient whose
ulcers remained completely healed for 6 months.
In LV, it is advisable to perform broad hematologic tests to
uncover the presence of a possible thrombogenic factor, asso-
ciated or not with an underlying autoimmune disorder. Even
when not documented by the presently available laboratory
methods, we stress the importance of antithrombotic treat-
ments (anticoagulant and fibrinolytic therapies) in the healing
of skin ulcers of LV. In the present case, as there was a
homozygous state for the C677T mutation of MTHFR, in
addition to persistent anticoagulation, folic acid supple-
mentation was advised in order to prevent thrombotic events
in other organs.
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